newwin
Luciann Nguyen
Settings
← Accounts
biotech

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

53
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

New trial — Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

New trialNCT07624214
53/100
Opportunity
Commercial fit11/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1 trial NCT07624214 posted by Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.: "Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors". New trial on a phase 1 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 97 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT07624214
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
phase 1
mol. elig.